Role of GH in regulating nocturnal rates of lipolysis and plasma mevalonate levels in normal and diabetic humans.
暂无分享,去创建一个
P. Cryer | A. Avogaro | D. Illingworth | P. Boyle | L. Smith | D. Bier | A. Pappu
[1] R. Steele,et al. Effect of ovine prolactin administration on free fatty acid metabolism in the normal dog. , 1971, Endocrinology.
[2] J. Clore,et al. Sleep-Associated Fall in Glucose Disposal and Hepatic Glucose Output in Normal Humans: Putative Signaling Mechanism Linking Peripheral and Hepatic Events , 1989, Diabetes.
[3] D L Horwitz,et al. Determination of Free and Total Insulin and C-Peptide in Insulin-treated Diabetics , 1977, Diabetes.
[4] N. Levin,et al. Relationship Between Renal Function and Metabolic Alterations in Early Streptozocin-Induced Diabetes in Rats , 1987, Diabetes.
[5] J. Aloia,et al. Absence of hyperlipidemia in acromegaly. , 1972, The Journal of clinical endocrinology and metabolism.
[6] S. Elek,et al. Pituitary Growth Hormone Essential for Regulation of Serum Cholesterol , 1970, Nature.
[7] N. Nurjhan,et al. Insulin Dose-Response Characteristics for Suppression of Glycerol Release and Conversion to Glucose in Humans , 1986, Diabetes.
[8] J. Dietschy,et al. Regulation of cholesterol metabolism. I. , 1970, The New England journal of medicine.
[9] T. Parker,et al. Role of the kidneys in the metabolism of plasma mevalonate. Studies in humans and in rhesus monkeys. , 1985, The Journal of clinical investigation.
[10] M. Davidson,et al. Suppression of Sleep-Induced Growth Hormone Secretion by Anticholinergic Agent Abolishes Dawn Phenomenon , 1988, Diabetes.
[11] B. Beaufrère,et al. Determination of steady state and nonsteady-state glycerol kinetics in humans using deuterium-labeled tracer. , 1987, Journal of lipid research.
[12] P. Cryer,et al. Pathogenesis of the dawn phenomenon in patients with insulin-dependent diabetes mellitus. Accelerated glucose production and impaired glucose utilization due to nocturnal surges in growth hormone secretion. , 1985, The New England journal of medicine.
[13] D. Schoeller,et al. Evidence for diurnal periodicity in human cholesterol synthesis. , 1990, Journal of lipid research.
[14] P. Cryer,et al. External and internal standards in the single-isotope derivative (radioenzymatic) measurement of plasma norepinephrine and epinephrine. , 1985, The Journal of laboratory and clinical medicine.
[15] T. Parker,et al. Plasma mevalonate as a measure of cholesterol synthesis in man. , 1984, The Journal of clinical investigation.
[16] P. Cryer,et al. Enhanced glycemic responsiveness to epinephrine in insulin-dependent diabetes mellitus is the result of the inability to secrete insulin. Augmented insulin secretion normally limits the glycemic, but not the lipolytic or ketogenic, response to epinephrine in humans. , 1985, The Journal of clinical investigation.
[17] J. White,et al. Lipolytic action of corticotropin on rat adipose tissue in vitro. , 1958, The Journal of clinical investigation.
[18] W. Nicholson,et al. Diurnal rhythm and disappearance half-time of endogenous plasma immunoreactive beta-MSH (LPH) and ACTH in man. , 1978, The Journal of clinical endocrinology and metabolism.
[19] P. Blackett,et al. Growth hormone in the regulation of hyperlipidemia. , 1982, Metabolism: clinical and experimental.
[20] R. Winter,et al. Serum cholesterol and triglycerides in children with growth hormone deficiency. , 1979, Metabolism: clinical and experimental.
[21] P. Sönksen,et al. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. , 1989, The New England journal of medicine.
[22] D. Kipnis,et al. Growth hormone secretion during sleep. , 1968, The Journal of clinical investigation.
[23] D. Schalch,et al. A Sensitive Double Antibody Immunoassay for Human Growth Hormone in Plasma , 1964, Nature.
[24] F. Cassorla,et al. The advantage of measuring stimulated as compared with spontaneous growth hormone levels in the diagnosis of growth hormone deficiency. , 1988, The New England journal of medicine.
[25] M. Davidson. Effect of growth hormone on carbohydrate and lipid metabolism. , 1987, Endocrine reviews.
[26] R. Pelkonen,et al. Serum lipids in acromegaly. , 1975, Metabolism: clinical and experimental.
[27] P. Cryer,et al. Epinephrine plasma metabolic clearance rates and physiologic thresholds for metabolic and hemodynamic actions in man. , 1980, The Journal of clinical investigation.
[28] P. Edwards,et al. Determination of mevalonate in blood plasma in man and rat. Mevalonate "tolerance" tests in man. , 1979, Journal of lipid research.
[29] A. Kawaguchi,et al. A new colorimetric method for the determination of free fatty acids with acyl-CoA synthetase and acyl-CoA oxidase. , 1981, Journal of biochemistry.
[30] S. Fineberg,et al. Studies of hyperlipidemia in the HGH-deficient state. , 1972, Metabolism: clinical and experimental.
[31] T. Parker,et al. Mevalonic acid in human plasma: relationship of concentration and circadian rhythm to cholesterol synthesis rates in man. , 1982, Proceedings of the National Academy of Sciences of the United States of America.